United Bank (Virginia)’s Trevi Therapeutics TRVI Stock Holding History

United Bank (Virginia)’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$372K	Hold	31,200	–	–	0.05%	105
2025 Q4	$391K	Hold	31,200	–	–	0.05%	99
2025 Q3	$285K	Hold	31,200	–	–	0.03%	110
2025 Q2	$171K	Hold	31,200	–	–	0.02%	135
2025 Q1	$196K	Hold	31,200	–	–	0.03%	133
2024 Q4	$129K	Hold	31,200	–	–	0.02%	129
2024 Q3	$104K	Hold	31,200	–	–	0.01%	135
2024 Q2	$93K	Buy	31,200 +2,750	+10%	+$7.64K	0.01%	135
2024 Q1	$98.2K	Hold	28,450	–	–	0.01%	140
2023 Q4	$38.1K	Hold	28,450	–	–	﹤0.01%	141
2023 Q3	$62K	Hold	28,450	–	–	0.01%	140
2023 Q2	$68K	Hold	28,450	–	–	0.01%	148
2023 Q1	$52.6K	Hold	28,450	–	–	0.01%	154
2022 Q4	$54.9K	Hold	28,450	–	–	0.01%	153
2022 Q3	$44K	Hold	28,450	–	–	0.01%	153
2022 Q2	$80K	Buy	28,450 +1,750	+7%	+$4.3K	0.01%	144
2022 Q1	$59K	Buy	+26,700	New	+$27.7K	0.01%	157

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

United Bank (Virginia)'s TRVI Position: Q1 2026 in Review

United Bank (Virginia) held its Trevi Therapeutics (TRVI) position steady in Q1 2026 at 31,200 shares worth $372K. The position accounts for 0.05% of the portfolio, ranked #105.

United Bank (Virginia) first reported a position in TRVI in Q1 2022 and has held it in 17 quarters since. The position peaked at $391K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

United Bank (Virginia) held 31,200 shares of Trevi Therapeutics worth $372K as of Q1 2026.
United Bank (Virginia) left its Trevi Therapeutics share count unchanged in Q1 2026.
Trevi Therapeutics made up 0.05% of United Bank (Virginia)'s portfolio in Q1 2026, its #105 holding.
United Bank (Virginia) first reported a position in Trevi Therapeutics in Q1 2022 and has held it in 17 quarters since.
United Bank (Virginia)'s Trevi Therapeutics position peaked at $391K in Q4 2025.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on United Bank (Virginia)'s 13F filing for Q1 2026, filed 11 May 2026.